Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy.

Creator(s)

Karishma Rao, Children's Mercy HospitalFollow
Sana Farooki, Children's Mercy Hospital
Erin M. Guest, Children's Mercy HospitalFollow
Katherine Chastain, Children's Mercy Hospital
Melissa Gener, Children's Mercy HospitalFollow
Gangaram Akangire, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

5-1-2021

Identifier

DOI: 10.1097/MPH.0000000000001907

Abstract

Inflammatory myofibroblastic tumors (IMTs) are rare in neonates. IMTs of the tongue are also very rare in infancy, with only 1 case reported in this age group. The mainstay of therapy has traditionally been surgery, which can be devastating to surrounding structures and negatively impact prognosis. Approximately 50% of IMTs harbor a translocation involving the anaplastic lymphoma kinase gene. We describe a case of IMT of the tongue in a neonate treated with debulking and an anaplastic lymphoma kinase inhibitor. The patient achieved complete response and remains disease-free 1.5 year following completion of therapy.

Journal Title

Journal of pediatric hematology/oncology : official journal of the American Society of Pediatric Hematology/Oncology

Volume

43

Issue

4

First Page

521

Last Page

524

Recommended Citation

Rao K, Farooki S, Guest E, Chastain K, Gener M, Akangire G. Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy. J Pediatr Hematol Oncol. 2021;43(4):e521-e524. doi:10.1097/MPH.0000000000001907